Masters Programme Endorsed by Leading Multinational Top 20 Pharmaceutical Companies Through the Asia Training Consortium
ClinTec International and Edinburgh Napier University are delighted to announce that the Asia Training Consortium has endorsed the Masters in International Clinical Research and Technology for clinical research professionals.
The Asia Training Consortium (ATC) was founded in 2012 as a unified platform for pharmaceutical companies to establish common goals and share resources to provide world-class training and development in clinical research in Asia. It is currently a consortium of 17 companies, including large top 20 pharmaceutical companies such as Merck, Novartis, Pfizer, Astellas and AstraZeneca, global CROs and training institutions including Edinburgh Napier University. This is the first endorsement from ATC of an academic qualification to meet the needs for further qualifications for research professionals.
The Masters in International Clinical Research and Technology was launched last year between Edinburgh Napier University and ClinTec International to support the development of clinical research staff throughout the world and has now been endorsed by the ATC. This innovative Masters programme is an exciting collaboration, which builds upon the clinical research and educational expertise that exists within these two organisations. The Masters programme is accessible globally and has enrolled students from 14 countries, including students based in UAE, Lebanon, South Africa, India and the Philippines, as well as from France, Austria, Sweden, UK, Czech Republic, Slovenia, Lithuania, Croatia and Romania. This successful innovative industry/academic collaboration leading to a Masters Degree led to ClinTec being awarded the Microsoft Innovation of the Year Award 2014 at the UK’s largest Business Award Ceremony, with guest speaker global entrepreneur, Sir Richard Branson. Over the last 5 years, ClinTec and Edinburgh Napier University have delivered clinical research courses to over 1000 clinical professionals globally, with over 200 based in Asia.
ClinTec International is a global CRO, with a presence in over 50 countries across 5 continents. On the occasion of the endorsement of the Masters programme by ATC, Dr Rabinder Buttar, Founder, Chairman and CEO of ClinTec International, commented: “ClinTec International is delighted to receive this endorsement from the Asia Training Consortium. As ClinTec has a global presence in over 50 countries, we are very pleased to be associated with a platform that provides world-class training and development in Asia”.
Professor Andrea Nolan, Principal and Vice-Chancellor of Edinburgh Napier University stated: “At Edinburgh Napier University we have a history of collaborating with industry to give students the best possible education to equip them to become leaders in their field. We are delighted to have the endorsement from the Asia Training Consortium who share the joint aspirations of providing world class training for clinical research professionals”.
John Constantine, Chair, Asia Training Consortium, said: “This is yet another example of collaboration within and across industries to further quality and excellence in clinical research. ATC membership is excited to have this endorsement between a respected University, Edinburgh Napier University, and ClinTec, one of the premier contract research organizations. I look forward to further collaborations like this between ATC members in the future.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...